Moderna 's ( MRNA -2.63%) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Moderna is deprioritizing certain parts of its pipeline, which involves pausing work on some products and scrapping others.

With the approval of Moderna's updated COVID-19 vaccine, doctors are hoping the shots will be available soon and Albertans ...

20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have ...

Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...

Shares of Moderna Inc. MRNA slipped 3.43% to $65.69 Friday, on what proved to be an all-around mixed trading session for the ...

Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending ...

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

Moderna shares are down for the second day in a row after the company said it would slash its research and development costs.

The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...

NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...